Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Autoimmune disease

Multiple sclerosis (MS)

G protein-coupled receptor 109A (GPR109A; HM74A; HCAR2)

Mouse studies suggest GPR109A activation is the mechanism of action for Tecfidera dimethyl fumarate and that activating GPR109A could help treat MS. In an experimental autoimmune encephalomyelitis (EAE) mouse model of MS, Tecfidera delayed CNS neutrophil infiltration and disease onset in Gpr109a+ mice but not in Gpr109a knockouts. Next steps include testing GPR109A agonists in mouse models of MS.
Biogen Idec Inc. markets Tecfidera, an oral formulation of dimethyl fumarate that activates the nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2) pathway, to treat MS.

SciBX 7(24); doi:10.1038/scibx.2014.695
Published online June 19, 2014

Unpatented; available for licensing

Chen, H. et al. J. Clin. Invest.;
published online May 1, 2014;
doi:10.1172/JCI72151
Contact: Markus Schwaninger, University of Luebeck, Luebeck, Germany
e-mail:
markus.schwaninger@pharma.uni-luebeck.de